These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 12778774)

  • 1. [Atherosclerosis and uremia: signifance of non-traditional risk factors].
    Hörl WH
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):220-34. PubMed ID: 12778774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of oxidative and carbonyl stress to long-term uremic complications.
    Miyata T; Kurokawa K; van Ypersele de Strihou C
    Kidney Int Suppl; 2000 Aug; 76():S120-5. PubMed ID: 10936808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular biology in uremia: insights into novel mechanisms of vascular injury.
    Al Aly Z; Edwards JC
    Adv Chronic Kidney Dis; 2004 Jul; 11(3):310-8. PubMed ID: 15241745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.
    Mallamaci F; Zoccali C
    J Ren Nutr; 2009 Jan; 19(1):25-8. PubMed ID: 19121766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
    Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
    Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease.
    Kielstein JT; Bode-Böger SM; Frölich JC; Haller H; Böger RH
    Kidney Int Suppl; 2001 Feb; 78():S9-13. PubMed ID: 11168975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Special characteristics of atherosclerosis in chronic renal failure.
    Amann K; Tyralla K; Gross ML; Eifert T; Adamczak M; Ritz E
    Clin Nephrol; 2003 Jul; 60 Suppl 1():S13-21. PubMed ID: 12940530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia.
    London GM; Marchais SJ; Guérin AP; Métivier F
    Curr Opin Nephrol Hypertens; 2005 Nov; 14(6):525-31. PubMed ID: 16205470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory and atherosclerotic interactions in the depleted uremic patient.
    Stenvinkel P
    Blood Purif; 2001; 19(1):53-61. PubMed ID: 11114578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherosclerosis in chronic renal failure.
    Charney DI; Walton DF; Cheung AK
    Curr Opin Nephrol Hypertens; 1993 Nov; 2(6):876-82. PubMed ID: 7922227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does uremia cause vascular dysfunction?
    Brunet P; Gondouin B; Duval-Sabatier A; Dou L; Cerini C; Dignat-George F; Jourde-Chiche N; Argiles A; Burtey S
    Kidney Blood Press Res; 2011; 34(4):284-90. PubMed ID: 21691132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease].
    Cozzolino M; Butti A; Chiarelli G; Rocca-Rey L; Santagostino G; Gallieni M; Brancaccio D
    Ital Heart J Suppl; 2005 Jan; 6(1):25-8. PubMed ID: 15776728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atherosclerosis and vascular calcification in hemodialysis patients].
    Hirasaka N; Liang XM; Mune M
    Clin Calcium; 2004 Jun; 14(6):85-90. PubMed ID: 15577060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
    Kielstein JT; Zoccali C
    Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative protein damage with carbohydrates and lipids in uremia: 'Carbonyl stress'.
    Inagi R; Miyata T
    Blood Purif; 1999; 17(2-3):95-8. PubMed ID: 10449866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench.
    El-Abbadi M; Giachelli CM
    Curr Opin Nephrol Hypertens; 2005 Nov; 14(6):519-24. PubMed ID: 16205469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice.
    Massy ZA; Ivanovski O; Nguyen-Khoa T; Angulo J; Szumilak D; Mothu N; Phan O; Daudon M; Lacour B; Drüeke TB; Muntzel MS
    J Am Soc Nephrol; 2005 Jan; 16(1):109-16. PubMed ID: 15563564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications.
    Miyata T; van Ypersele de Strihou C; Kurokawa K; Baynes JW
    Kidney Int; 1999 Feb; 55(2):389-99. PubMed ID: 9987064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AGEs and carbonyl stress: potential pathogenetic factors of long-term uraemic complications.
    Zoccali C; Mallamaci F; Tripepi G
    Nephrol Dial Transplant; 2000; 15 Suppl 2():7-11. PubMed ID: 11051031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.